Selection criteria for the expected management of localised prostate cancer;Selektionskriterien zum abwartenden management des lokalisierten prostatakarzinoms

Urologe - Ausgabe A

Volumn 44, Issue 11, 2005, Pages 1277-1286

  Graefen, M ^a   Salomon, G ^a   Currlin, E ^a   Eichelberg, C ^a   Schlomm, T ^a   Huland, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Comorbidity; Expectant management; Insignificant cancer; Overtreatment; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; COMORBIDITY; DIAGNOSTIC PROCEDURE; HUMAN; LIFE EXPECTANCY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

DECISION SUPPORT SYSTEMS, CLINICAL; DECISION SUPPORT TECHNIQUES; GERMANY; HUMANS; MALE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL; THERAPY, COMPUTER-ASSISTED;

EID: 27944475273     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-005-0924-3     Document Type: Article

References (38)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 293(17): 2095-2101
2. Alibhai SMH, Krahn MD, Cohen MM (2000) Older patents receive less aggressive treatment for clinically localized prostate cancer. Clin Invest Med 23: 332
3. Anast JW, Andriole GL, Bismar TA, Yan Y, Humphrey PA (2004) Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population? Urology 64(3): 544-550
4. Augustin H, Hammerer PG, Graefen M et al. (2003) Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol 43(5): 455-460
5. Barry MJ, Albertsen PC, Bagshaw MA et al. (2001) Outcomes for Men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy or expectant management. Cancer 91: 2302-2314
6. Carter HB, Sauvageot J, Walsh PC, Epstein JI (1997) Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. J Urol 157(6): 2206-2209
7. Carter HB, Walsh PC, Landis P, Epstein JI (2002) Expectant management of non palpable prostate cancer with curative intent: preliminary results. J Urol 167(3): 1231-1234
8. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5): 373-383
9. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, Carroll PR; CaPSURE Investigators (2004) The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171(4): 1393-1401
10. Cupp MR, Bostwick DG, Myers RP, Oesterling JE (1995) The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 153(5): 1543-1548
11. Epstein JI, Chan DW, Sokoll LJ et al. (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160(6 Pt 2): 2407-2411
12. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271(5): 368-374
13. Elgamal AA, Van Poppel HP, Van deVoorde WM, Van Dorpe JA, Oyen RH, Baert LV (1997) Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 157(1): 244-250
14. Franks LM (1954) Latent carcinoma of the prostate. J Pathol Bacteriol 68(2): 603-616
15. Froehner M, Koch R, Litz R, Oehlschlaeger S, Wirth MP (2004) Which conditions contributing to the charlson score predict survival after radical prostatectomy J Urol 171: 697-699
16. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT (1996) Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 156(3): 1059-1063
17. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE, Norlen BJ; Scandinavian Prostatic Cancer Group Study Number 4 (2002) A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347(11): 781-789
18. Irwin MB, Trapasso JG (1994) Identification of insignificant prostate cancers: analysis of preoperative parameters Urology 44(6): 862-867
19. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52(1): 23-47
20. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, Adami HO (2004) Natural history of early, localized prostate cancer. JAMA 291(22): 2713-2719
21. Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chron Dis 27: 387-404
22. Kattan MW, Eastham JA, Wheeler TM et al. (2003) Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170(5): 1792-1797
23. Klein EA (2004) What is, insignificant' prostate carcinoma? Cancer 101(9): 1923-1925
24. Noguchi M, Stamey TA, McNeal JE, Yemoto CM (2001) Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 166(1): 104-109
25. Panagiotou I, Beer TM, Hsieh YC, Mori M, Peters L, Klein T, Garzotto M (2004) Predictors of delayed therapy after expectant management for localized prostate cancer in the era of prostate-specific antigen. Oncology 67(3-4): 194-202
26. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT (2004) An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 171(4): 1520-1524
27. Schlomm T, Luebke AM, Sultmann H et al. (2005) Extraction and processing of high quality RNA from impalpable and macroscopically invisible prostate cancer for microarray gene expression analysis. Int J Oncol 27(3): 713-720
28. Shabbir Alibhai SM, Naglie G, Nam R, Trachtenberg J, Krahn MD (2003) Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 21(17): 3318-3327
29. Schirrmacher F (2004) Das Methusalem-Komplott. Blessing, München
30. Singh R, O'Brien TS (2004) Comorbidity assessment in localized prostate cancer: A review of currently available techniques. Eur Urol 46: 28-41
31. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP (1993) Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 71(3 Suppl): 933-938
32. Steinberg GD, Bales GT, Brendler CB (1998) An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159(5): 1431-1436
33. Sweat SD, Bergstralh EJ, Slezak J, Blute ML, Zincke H(2002) Competing risk analysis after radical prostatectomy for clincally nonmetastatic prostate adenocarcinoma according to clincal gleason score and patient age. J Urol 168: 525-529
34. StatistischesBundesamt 004:http://www.destatis.de/download/d/bevoe/ sterbet03.xls
35. Thompson KE, Hernandez J, Canby-Hagino ED, Troyer D, Thompson IM (2005) Prognostic features in men who died of prostate cancer. J Urol 174(2): 553-556
36. Wirth MP, Froehner M (2004) he significance of comorbidity and age in radical prostatectomy. Urologe A 43(10): 935-941
37. Wu H, Sun L, Moul JW et al. (2004) Watchful waiting and factors predictive of secondary treatment of localized prostate cancer. J Urol 171(3): 1111-1116
38. Yan Y, Carcalhal GF, Catalona WJ (2000) Primary treatment choices form men with clinically localized prostate carcinoma detected by screening. Cancer 88: 1112-1130